“North America’s extremity tissue expanders market is anticipated to reach USD 99.63 Million by 2030”, says Visiongain

29 November 2019
Pharma

Visiongain has launched a new pharma report ‘’North America Extremity Tissue Expanders Market Report 2020-2030’’ by Shape (Anatomical, Crescent, Rectangular, Round, Others), End Users (Burn Centers, Hospitals, Others), and Geography.

North America's extremity tissue expanders market is anticipated to grow at a lucrative CAGR of 3.8% and anticipated to reach USD 99.63 Million by 2030.

The increasing number of trauma-related injuries and cases of serious road accidents are considered to be one of the most significant factors contributing to demand for the drug.

According to the United States Fire Administration, in the year 2015, over 15,000 people suffered burns. Accidents may result in severe upper and lower extremity injuries, as well as bruises and deformities. This often leads to reconstructive surgery with the help of tissue expanders.

Increasing prevalence of congenital deformity and birth defects has also resulted in high market development as congenital abnormalities or birth defects involving lower & upper extremities may involve reconstruction procedures based on tissue expander.

Also, some of the major factors contributing to the growth of North American extremity tissue expanders market are technological advancements, growing tissue expander awareness, improvement in quality patient care, and growing healthcare expenditure. A near-perfect match of color & texture, a high success rate of effective tissue grafting, and limited scarring are some of the advantages of these products.

Due to the presence of developed healthcare facilities, growing healthcare expenditure, and the widespread prevalence of multiple congenital disorders, the United States dominated the North American extremity tissue expanders market in 2018. Also, as per the CDC, in the United States, 1 out of 33 babies born are affected by a birth defect. However, an increase in the number of reconstructive surgeries in the country has resulted in a high demand for these products.

During the forecast period from 2020 to 2030, Canada's extremity tissue expanders market is anticipated to grow at a lucrative CAGR. The growing number of road accidents & trauma injuries have increased demand for these expanders in surgical procedures for leg and arm reconstruction.

North America holds the majority of market share followed by Europe and will continue to dominate in the future as a result of several research projects in the region, coupled with funding for research institutes from the government. Also, the market will continue to be driven by the existence of the target population and increased R&D investment by important business organizations.

Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products to strengthen their position in the extremity tissue expanders market. Companies are also expanding their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the extremity tissue expanders market.

The comprehensive market report features companies such as Allergan plc, KOKEN CO., LTD., Mentor Worldwide LLC, PMT Corporation, Sientra, Inc., Eurosilicone S.A.S., Eurosurgical Ltd., Guangzhou Wanhe Plastic Materials Co. Ltd., Groupe Sebbin, GC Aesthetics PLC, Koken Co. Ltd, Laboratories Arion, Oxtex Ltd., Polytech, Specialty Surgical Products, Inc.., Wright Medical Group among other prominent players. Also, the research study offers market estimation and forecast for the period ranging from 2020-2030 for North America along with regional sub-markets as the U.S. and Canada.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Biological API Manufacturing Services Market Report 2021-2031

Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.

08 January 2021

Read

Visiongain Publishes Anaesthesia & Respiratory Devices Market Report 2020-2030

The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.

07 January 2021

Read

Visiongain Publishes Inactivated Vaccines Market Report 2020-2030

Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.

07 January 2021

Read

Visiongain Publishes Human Microbiome Therapeutics Market Report 2021-2031

The potential of microbiome-based drugs as novel treatments to address the unmet needs for many diseases has contributed intensively to the rapid emergence of many investors in this area. Currently, no regulatory framework exists and no drugs have received FDA approval. However, there are several preclinical and clinical-stage companies working with various approaches to develop microbiome-based therapies.

06 January 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever